Andrew D Huber

12PUBLICATIONS
23CO-AUTHORS
PharmacogenomicsReaction engineering (excl. nuclear reactions)Molecular targetsCheminformatics and quantitative structure-activity relationshipsBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 23, 2026
Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.

|Nov 06, 2025
PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors.

Andrew D Huber, Wenwei Lin, Young-Hwan Jung

|Oct 15, 2024
First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy.

Andrew D Huber, Young-Hwan Jung, Yongtao Li

|Aug 19, 2024
A new mode of inhibition.

Andrew D Huber, Taosheng Chen

|May 14, 2024
Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR.

Efren Garcia-Maldonado, Andrew D Huber, Sergio C Chai

|Dec 12, 2023
A bromodomain-independent mechanism of gene regulation by the BET inhibitor JQ1: direct activation of nuclear receptor PXR.

Andrew D Huber, Shyaron Poudel, Jing Wu

Pageof 2

Frequent Collaborators

8 joint publications

Taosheng Chen

4 joint publications

Wenwei Lin

2 joint publications

Philip R Tedbury

2 joint publications

Sergio C Chai